Efficacy of Disitamab Vedotin in Non-small Cell Lung Cancer with Alterations: a Multicenter, Retrospective Real-world Study

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Nov 21

PMID 39568568

Authors

Meiling Zhang

Li Wang

Qian Wang

Jiu Yang

Wei Peng

Xiaoyou Li

Meiqi Shi

Kaihua Lu

Affiliations

Soon will be listed here.

Abstract

Background: Non-small cell lung cancer (NSCLC) with human epidermal growth factor receptor 2 () alterations poses a substantial treatment challenge. Current -targeted therapies offer limited efficacy. Antibody-drug conjugates (ADCs) targeting have emerged as a promising therapeutic strategy. This study aimed to evaluate the clinical response to a novel ADC drug Disitamab vedotin (RC48) in advanced NSCLC with alterations.

Methods: This study conducted a retrospective review of patients harboring alterations treated with RC48 in the real world. Clinical outcomes were evaluated in terms of objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS).

Results: Out of 22 patients, 21 (95.5%) received RC48 combination therapy, while one received RC48 monotherapy. The ORR of all patients reached 45.5%, and the DCR stood at 90.9%. The median PFS (mPFS) was 7.5 months. Among patients receiving RC48 combination therapy, the ORR was 47.7%, and the mPFS of 8.1 months. The combination of RC48 with platinum+/- bevacizumab resulted in the highest ORR of 71.4% (5 out of 7 patients), with TKI following at a 50.0% ORR (4 out of 8 patients). First-line (1L) treatment with RC48 showed an ORR of 62.5% (5 out of 8 patients), second-line (2L) treatments had a 57.1% ORR (4 out of 7 patients), and beyond second-line (>2L) treatments exhibited a 14.3% ORR (1 out of 7 patients). Patients with 1L, 2L, or >2L treatment had a mPFS of 8.1 months, 7.2 months, and 7.4 months, respectively. Patients with mutations or amplifications, and those with concurrent mutations and amplifications at baseline, showed mPFS of 8.1 months, 9.4 months, and 7.4 months, respectively. The mPFS was significantly longer in patients with amplification. The most common adverse events included hand-foot syndrome (54.5%), asthenia (50.0%), decreased white blood cell count (45.5%), and liver impairment (45.5%). Grade 3 adverse events occurred in one (4.5%) patient.

Conclusion: RC48, particularly in combination regimens, demonstrates promising efficacy in advanced NSCLC with alterations. These findings underscore the need for further research to validate RC48's application in clinical practice.

References

Chau C, Steeg P, Figg W . Antibody-drug conjugates for cancer. Lancet. 2019; 394(10200):793-804. DOI: 10.1016/S0140-6736(19)31774-X. View

Dziadziuszko R, Smit E, Dafni U, Wolf J, Wasag B, Biernat W . Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). J Thorac Oncol. 2019; 14(6):1086-1094. DOI: 10.1016/j.jtho.2019.02.017. View

Jebbink M, de Langen A, Boelens M, Monkhorst K, Smit E . The force of HER2 - A druggable target in NSCLC?. Cancer Treat Rev. 2020; 86:101996. DOI: 10.1016/j.ctrv.2020.101996. View

Langer C, Stephenson P, Thor A, Vangel M, Johnson D . Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol. 2004; 22(7):1180-7. DOI: 10.1200/JCO.2004.04.105. View

Li H, Yu C, Jiang J, Huang C, Yao X, Xu Q . An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer. Cancer Biol Ther. 2016; 17(4):346-54. PMC: 4910924. DOI: 10.1080/15384047.2016.1139248. View

Ponte J, Ab O, Lanieri L, Lee J, Coccia J, Bartle L . Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia. 2016; 18(12):775-784. PMC: 5126132. DOI: 10.1016/j.neo.2016.11.002. View

Nie C, Xu W, Guo Y, Gao X, Lv H, Chen B . Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study. BMC Cancer. 2023; 23(1):1239. PMC: 10724908. DOI: 10.1186/s12885-023-11735-z. View

Chen M, Yao K, Cao M, Liu H, Xue C, Qin T . HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study. Cancer Immunol Immunother. 2023; 72(7):2309-2318. PMC: 10264489. DOI: 10.1007/s00262-023-03419-1. View

Le X, Cornelissen R, Garassino M, Clarke J, Tchekmedyian N, Goldman J . Poziotinib in Non-Small-Cell Lung Cancer Harboring Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. J Clin Oncol. 2021; 40(7):710-718. PMC: 8887939. DOI: 10.1200/JCO.21.01323. View

10.

Quanz M, Hagemann U, Zitzmann-Kolbe S, Stelte-Ludwig B, Golfier S, Elbi C . Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models. Oncotarget. 2018; 9(75):34103-34121. PMC: 6183338. DOI: 10.18632/oncotarget.26135. View

11.

Passaro A, Janne P, Peters S . Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies. J Clin Oncol. 2023; 41(21):3747-3761. DOI: 10.1200/JCO.23.00013. View

12.

Elamin Y, Robichaux J, Carter B, Altan M, Gibbons D, Fossella F . Poziotinib for Patients With Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol. 2021; 40(7):702-709. PMC: 8887948. DOI: 10.1200/JCO.21.01113. View

13.

Chen J, Xu C, Wang Q, Lv J, Lu W, Zhang Y . Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study. Lung Cancer. 2023; 183:107315. DOI: 10.1016/j.lungcan.2023.107315. View

14.

Song Z, Yu X, Shi Z, Zhao J, Zhang Y . HER2 mutations in Chinese patients with non-small cell lung cancer. Oncotarget. 2016; 7(47):78152-78158. PMC: 5363651. DOI: 10.18632/oncotarget.11313. View

15.

Nutzinger J, Lee J, Low J, Chia P, Wijaya S, Cho B . Management of HER2 alterations in non-small cell lung cancer - The past, present, and future. Lung Cancer. 2023; 186:107385. DOI: 10.1016/j.lungcan.2023.107385. View

16.

Liu S, Tu H, Wei X, Yan H, Dong X, Cui J . First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial. Nat Med. 2023; 29(8):2079-2086. DOI: 10.1038/s41591-023-02461-x. View

17.

Oh D, Bang Y . HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2019; 17(1):33-48. DOI: 10.1038/s41571-019-0268-3. View

18.

Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M . Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug Deliv. 2022; 29(1):1335-1344. PMC: 9090390. DOI: 10.1080/10717544.2022.2069883. View

19.

Jain R . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7(9):987-9. DOI: 10.1038/nm0901-987. View

20.

Zhang S, Wang W, Xu C, Zhang Y, Cai X, Wang Q . Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer. Thorac Cancer. 2022; 14(1):91-104. PMC: 9807451. DOI: 10.1111/1759-7714.14743. View